// App-Quantinova.ai

: Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting ß2-agonist (LABA/LAMA) in the UK

Researchers

Presenter

  • Gema Requena

Principal Investigators

  • Victoria Banks

  • Alexandrosz Czira

  • Robert Wood

  • Theo Tritton

  • Eunmi Ha

  • Rosie Wild

  • Chris Compton

  • Afisi Ismaila

Medical Centers

  • Adelphi Real World, Observational Research Department, Bollington, Cheshire, United Kingdom

  • GSK, R&D Global Medical, Brentford, Middlesex, United Kingdom

  • GSK, R&D Global Medical, Collegeville, PA, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved